JCR Pharmaceuticals Co., Ltd. (TYO: 4552)
Japan
· Delayed Price · Currency is JPY 585.00
-7.00 (-1.18%)
Jan 9, 2025, 3:45 PM JST
JCR Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 35,256 | 42,871 | 34,343 | 51,082 | 30,085 | 24,781 | Upgrade
|
| Revenue Growth (YoY) | -18.07% | 24.83% | -32.77% | 69.79% | 21.40% | 7.00% | Upgrade
|
| Cost of Revenue | 10,069 | 11,620 | 8,886 | 10,461 | 7,812 | 7,901 | Upgrade
|
| Gross Profit | 25,187 | 31,251 | 25,457 | 40,621 | 22,273 | 16,880 | Upgrade
|
| Selling, General & Admin | 14,058 | 12,485 | 11,678 | 13,511 | 8,643 | 7,638 | Upgrade
|
| Research & Development | 11,234 | 11,234 | 8,802 | 7,175 | 5,360 | 5,997 | Upgrade
|
| Operating Expenses | 25,390 | 23,719 | 20,480 | 20,686 | 13,984 | 13,635 | Upgrade
|
| Operating Income | -203 | 7,532 | 4,977 | 19,935 | 8,289 | 3,245 | Upgrade
|
| Interest Expense | -109 | -86 | -44 | -45 | -42 | -22 | Upgrade
|
| Interest & Investment Income | 168 | 137 | 61 | 35 | 32 | 44 | Upgrade
|
| Earnings From Equity Investments | -981 | -1,090 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -308 | 767 | 387 | 551 | 206 | 8 | Upgrade
|
| Other Non Operating Income (Expenses) | -52 | 2 | 56 | 35 | 21 | 17 | Upgrade
|
| EBT Excluding Unusual Items | -1,485 | 7,262 | 5,437 | 20,511 | 8,506 | 3,292 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 10 | - | 22 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -15 | -20 | -36 | -2 | -5 | -2 | Upgrade
|
| Other Unusual Items | 1,065 | - | - | -1,106 | 129 | 131 | Upgrade
|
| Pretax Income | -435 | 7,242 | 5,411 | 19,403 | 8,652 | 3,421 | Upgrade
|
| Income Tax Expense | -29 | 1,707 | 1,625 | 4,886 | 1,764 | 742 | Upgrade
|
| Earnings From Continuing Operations | -406 | 5,535 | 3,786 | 14,517 | 6,888 | 2,679 | Upgrade
|
| Minority Interest in Earnings | -31 | -28 | -14 | -10 | 4 | -1 | Upgrade
|
| Net Income | -437 | 5,507 | 3,772 | 14,507 | 6,892 | 2,678 | Upgrade
|
| Net Income to Common | -437 | 5,507 | 3,772 | 14,507 | 6,892 | 2,678 | Upgrade
|
| Net Income Growth | - | 46.00% | -74.00% | 110.49% | 157.36% | -27.91% | Upgrade
|
| Shares Outstanding (Basic) | 125 | 125 | 124 | 124 | 124 | 123 | Upgrade
|
| Shares Outstanding (Diluted) | 125 | 125 | 125 | 124 | 124 | 124 | Upgrade
|
| Shares Change (YoY) | -0.32% | 0.45% | 0.51% | 0.06% | 0.07% | 0.14% | Upgrade
|
| EPS (Basic) | -3.50 | 44.13 | 30.34 | 117.26 | 55.80 | 21.72 | Upgrade
|
| EPS (Diluted) | -3.50 | 43.92 | 30.22 | 116.80 | 55.53 | 21.59 | Upgrade
|
| EPS Growth | - | 45.33% | -74.13% | 110.34% | 157.20% | -28.01% | Upgrade
|
| Free Cash Flow | 1,002 | 7,786 | -13,154 | -2,044 | 5,561 | 89 | Upgrade
|
| Free Cash Flow Per Share | 8.02 | 62.09 | -105.37 | -16.46 | 44.80 | 0.72 | Upgrade
|
| Dividend Per Share | 20.000 | 20.000 | 20.000 | 20.000 | 11.500 | 8.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 0% | 73.91% | 43.75% | 6.67% | Upgrade
|
| Gross Margin | 71.44% | 72.90% | 74.13% | 79.52% | 74.03% | 68.12% | Upgrade
|
| Operating Margin | -0.58% | 17.57% | 14.49% | 39.03% | 27.55% | 13.09% | Upgrade
|
| Profit Margin | -1.24% | 12.85% | 10.98% | 28.40% | 22.91% | 10.81% | Upgrade
|
| Free Cash Flow Margin | 2.84% | 18.16% | -38.30% | -4.00% | 18.48% | 0.36% | Upgrade
|
| EBITDA | 3,326 | 10,729 | 6,974 | 21,880 | 10,181 | 4,679 | Upgrade
|
| EBITDA Margin | 9.43% | 25.03% | 20.31% | 42.83% | 33.84% | 18.88% | Upgrade
|
| D&A For EBITDA | 3,529 | 3,197 | 1,997 | 1,945 | 1,892 | 1,434 | Upgrade
|
| EBIT | -203 | 7,532 | 4,977 | 19,935 | 8,289 | 3,245 | Upgrade
|
| EBIT Margin | -0.58% | 17.57% | 14.49% | 39.03% | 27.55% | 13.09% | Upgrade
|
| Effective Tax Rate | - | 23.57% | 30.03% | 25.18% | 20.39% | 21.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.